Insulet Co. (NASDAQ:PODD) Receives $132.69 Consensus PT from Analysts

Shares of Insulet Co. (NASDAQ:PODD) have received a consensus rating of “Buy” from the seventeen research firms that are covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $132.69.

Several research firms have recently weighed in on PODD. Canaccord Genuity lifted their target price on Insulet from $110.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, August 6th. Jefferies Financial Group lifted their target price on Insulet from $105.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, August 6th. Morgan Stanley lifted their target price on Insulet from $127.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 6th. BMO Capital Markets lifted their target price on Insulet from $130.00 to $150.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 6th. Finally, UBS Group lifted their target price on Insulet from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th.

In other news, insider Shacey Petrovic sold 895 shares of the firm’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $113.00, for a total transaction of $101,135.00. Following the transaction, the insider now owns 95,559 shares in the company, valued at $10,798,167. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Sally Crawford sold 28,347 shares of the firm’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $108.60, for a total value of $3,078,484.20. Following the transaction, the director now owns 28,469 shares in the company, valued at approximately $3,091,733.40. The disclosure for this sale can be found here. Company insiders own 3.50% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Manchester Capital Management LLC purchased a new position in Insulet in the first quarter valued at about $31,000. Advisors Preferred LLC purchased a new position in Insulet in the second quarter valued at about $38,000. Harvest Fund Management Co. Ltd purchased a new position in Insulet in the second quarter valued at about $43,000. Meridian Wealth Management LLC purchased a new position in Insulet in the first quarter valued at about $48,000. Finally, Quadrant Capital Group LLC grew its stake in Insulet by 1,037.7% in the first quarter. Quadrant Capital Group LLC now owns 603 shares of the medical instruments supplier’s stock valued at $55,000 after purchasing an additional 550 shares during the last quarter.

PODD traded down $1.10 during trading on Friday, reaching $154.09. The company had a trading volume of 414,150 shares, compared to its average volume of 672,745. Insulet has a 52 week low of $70.80 and a 52 week high of $158.18. The stock has a market cap of $9.35 billion, a P/E ratio of 3,081.80 and a beta of 1.08. The business has a 50 day simple moving average of $132.04 and a 200-day simple moving average of $107.18. The company has a quick ratio of 3.91, a current ratio of 4.72 and a debt-to-equity ratio of 2.43.

Insulet (NASDAQ:PODD) last released its earnings results on Monday, August 5th. The medical instruments supplier reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). Insulet had a return on equity of 7.85% and a net margin of 2.66%. The business had revenue of $177.10 million for the quarter, compared to the consensus estimate of $163.63 million. During the same quarter last year, the business posted ($0.03) earnings per share. The firm’s revenue for the quarter was up 42.5% compared to the same quarter last year. As a group, equities research analysts expect that Insulet will post 0.26 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Read More: What is meant by holder of record?

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.